Abstract 135P
Background
Despite significant advances in multimodality treatments, hepatocellular carcinoma (HCC) remains one of the common malignant tumors. Tumor microenvironments play an important role in progress of HCC. The study aimed to identify potential key genes associated with tumor microenvironments and prognosis of HCC.
Methods
The infiltration level of immune cells and stromal cells were calculated and quantified based on the ESTIMATE algorithm. Differentially expressed genes (DEGs) between high and low groups according to immune or stromal scores were screened using the gene expression profile of HCC pateitns in The Cancer Genome Atlas (TCGA) and were further linked to prognosis of HCC. These genes were validated in four independent HCC cohorts. Survival-related key genes were identified by LASSO Cox regression model.
Results
HCC patients with high immune/stromal score had better survival benefits than patients with low score. A total of 899 DEGs were identified and involved in immune responses and extracellular matrices, 147 of which were associated with overall survival. Subsequently, 52 of 147 survival-related DEGs were valided in additional cohorts. Finally, 10 key genes were selected (STSL2, TMC5, DOK5, RASGRP2, NLRC3, KLRB1, CD5L, CFHR3, ADH1C and UGT2B15) and used to construct a prognostic gene signature, presenting good performance in predicting overall survival.
Conclusions
This study extracted a list of genes associated with tumor microenvironments and the prognosis of HCC and would provide several valuable directions for the prognostic prediction and molecular targeted therapy of HCC in the future.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Xiujun Cai.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
9P - XRCC1 Arg194Trp, Palb2 T1100T (3300T>G), HMMR V353A, TNF aG308A polymorphisms as diagnostic and prognostic markers of breast cancer in the Kyrgyz ethnic group
Presenter: Aigul Semetei kyzy
Session: Poster display session
Resources:
Abstract
232P - Early Results from the Phase I Study of SY-1365, a Potent and Selective CDK7 inhibitor, in Patients with Ovarian Cancer and Advanced Solid Tumors
Presenter: Debra Richardson
Session: Poster display session
Resources:
Abstract
382P - Drug metabolizing enzymes pharmacogenomic: Biomarkers for improved chemotherapy in head and neck cancer squamous cell carcinoma
Presenter: Sunishtha Bhatia
Session: Poster display session
Resources:
Abstract
401P - Women in oncology: Alarming figures from India
Presenter: Sharada Mailankody
Session: Poster display session
Resources:
Abstract
416P - Multidisciplinary management of sarcomas of the head and neck: An institutional experience
Presenter: Kavitha Jain
Session: Poster display session
Resources:
Abstract
523P - Co-morbilities and survival of patients initially diagnosed with extensive-stage small cell lung cancer: Impact of hypertension, diabetes and chronic hepatitis B viral infection
Presenter: Weigang Xiu
Session: Poster display session
Resources:
Abstract
529P - Osimertinib for patients with EGFR-mutant advanced NSCLC and asymptomatic brain metastases: An open-label, two-arm, phase II study
Presenter: Roni Gillis
Session: Poster display session
Resources:
Abstract